Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAS-modulating multi-drug regimen for relapsed advanced cancers including glioblastoma
ACTRN12619001078145Phase 2Terminated
- Sponsor
- Gillies McIndoe Research Institute
- Start
- Apr 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of aliskiren, aspirin, celecoxib, curcumin, metformin and 5 more, sponsored by Gillies McIndoe Research Institute. Started Apr 2018; status: terminated.
02
Drugs
aliskirenaspirincelecoxibcurcuminmetformin
Beyond the preview
Go deeper on ACTRN12619001078145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001078145.